KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) EPS (Weighted Average and Diluted): 2019-2024

Historic EPS (Weighted Average and Diluted) for Aurinia Pharmaceuticals (AUPH) over the last 6 years, with Dec 2024 value amounting to $0.04.

  • Aurinia Pharmaceuticals' EPS (Weighted Average and Diluted) rose 130.00% to $0.23 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.56, marking a year-over-year increase of 473.33%. This contributed to the annual value of $0.04 for FY2024, which is 107.41% up from last year.
  • According to the latest figures from FY2024, Aurinia Pharmaceuticals' EPS (Weighted Average and Diluted) is $0.04, which was up 107.41% from -$0.54 recorded in FY2023.
  • Aurinia Pharmaceuticals' 5-year EPS (Weighted Average and Diluted) high stood at $0.04 for FY2024, and its period low was -$1.40 during FY2021.
  • Over the past 3 years, Aurinia Pharmaceuticals' median EPS (Weighted Average and Diluted) value was -$0.54 (recorded in 2023), while the average stood at -$0.42.
  • Per our database at Business Quant, Aurinia Pharmaceuticals' EPS (Weighted Average and Diluted) slumped by 60.92% in 2021 and then soared by 107.41% in 2024.
  • Over the past 5 years, Aurinia Pharmaceuticals' EPS (Weighted Average and Diluted) (Yearly) stood at -$0.87 in 2020, then plummeted by 60.92% to -$1.40 in 2021, then spiked by 45.71% to -$0.76 in 2022, then climbed by 28.95% to -$0.54 in 2023, then skyrocketed by 107.41% to $0.04 in 2024.